KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Long-Term Investments (2016 - 2024)

Supernus Pharmaceuticals (SUPN) has disclosed Long-Term Investments for 13 consecutive years, with $11.7 million as the latest value for Q1 2024.

  • Quarterly Long-Term Investments fell 78.47% to $11.7 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $11.7 million through Mar 2024, down 78.47% year-over-year, with the annual reading at $16.6 million for FY2023, 82.3% down from the prior year.
  • Long-Term Investments for Q1 2024 was $11.7 million at Supernus Pharmaceuticals, down from $16.6 million in the prior quarter.
  • The five-year high for Long-Term Investments was $534.7 million in Q1 2020, with the low at $11.7 million in Q1 2024.
  • Average Long-Term Investments over 5 years is $215.4 million, with a median of $131.9 million recorded in 2022.
  • The sharpest move saw Long-Term Investments increased 24.2% in 2021, then tumbled 82.3% in 2023.
  • Over 5 years, Long-Term Investments stood at $350.4 million in 2020, then crashed by 65.99% to $119.2 million in 2021, then dropped by 21.21% to $93.9 million in 2022, then crashed by 82.3% to $16.6 million in 2023, then dropped by 29.82% to $11.7 million in 2024.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $11.7 million, $16.6 million, and $25.1 million for Q1 2024, Q4 2023, and Q3 2023 respectively.